Evidence map›Paper›PMID 39424601›Full record

ArticleFEMS yeast research2024

Improving the Z3EV promoter system to create the strongest yeast promoter.

Rina Higuchi, Yuri Fujita, Shotaro Namba, Hisao Moriya

Abstract read
In one paragraph

Article in FEMS yeast research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rina HiguchiGraduate School of Environmental, Life, Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.
Yuri FujitaGraduate School of Environmental, Life, Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.
Shotaro NambaGraduate School of Environmental, Life, Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.
Hisao MoriyaFaculty of Environmental, Life, Natural Science and Technology, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0001-7638-3640

Funding

KAKENHI 24K02013
6 · The paper itself

Abstract

Promoters for artificial control of gene expression are central tools in genetic engineering. In the budding yeast Saccharomyces cerevisiae, a variety of constitutive and controllable promoters with different strengths have been constructed using endogenous gene promoters, synthetic transcription factors and their binding sequences, and artificial sequences. However, there have been no attempts to construct the highest strength promoter in yeast cells. In this study, by incrementally increasing the binding sequences of the synthetic transcription factor Z3EV, we were able to construct a promoter (P36) with ~1.4 times the strength of the TDH3 promoter. This is stronger than any previously reported promoter. Although the P36 promoter exhibits some leakage in the absence of induction, the expression induction by estradiol is maintained. When combined with a multicopy plasmid, it can express up to ~50% of total protein as a heterologous protein. This promoter system can be used to gain knowledge about the cell physiology resulting from the ultimate overexpression of excess proteins and is expected to be a useful tool for heterologous protein expression in yeast.

Indexed as

Gene Expression Regulation, FungalPlasmidsPromoter Regions, GeneticSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsTranscription FactorsGenetic EngineeringGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)Saccharomyces cerevisiae ProteinsTDH3 protein, S cerevisiaeTranscription Factorsoverexpressionpromoteryeast

Identifiers

PMID39424601
PMCPMC11523633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.